What’s Next for Navidea Biopharmaceuticals Incorporated (NYSEMKT:NAVB) After Having Less Shares Shorted?

July 17, 2017 - By Hazel Jackson

 What's Next for Navidea Biopharmaceuticals Incorporated (NYSEMKT:NAVB) After Having Less Shares Shorted?

Investors sentiment increased to 0.72 in 2016 Q4. Its up 0.33, from 0.39 in 2016Q3. It improved, as 6 investors sold Navidea Biopharmaceuticals Inc shares while 12 reduced holdings. 5 funds opened positions while 8 raised stakes. 13.64 million shares or 1.81% less from 13.89 million shares in 2016Q3 were reported.
Moreover, Ameriprise Fincl has 0% invested in Navidea Biopharmaceuticals Inc (NYSEMKT:NAVB) for 13,100 shares. 144,906 are held by Bancorp Of New York Mellon Corp. Hightower Advisors Llc holds 0% or 166,066 shares. Northern Trust Corporation, a Illinois-based fund reported 224,558 shares. Guggenheim Capital Ltd reported 49,927 shares or 0% of all its holdings. Boston Private Wealth Limited Liability Corp accumulated 46,262 shares or 0% of the stock. Jane Street Grp Incorporated Limited Company reported 0% in Navidea Biopharmaceuticals Inc (NYSEMKT:NAVB). Kcg Incorporated owns 0% invested in Navidea Biopharmaceuticals Inc (NYSEMKT:NAVB) for 15,086 shares. California Pub Employees Retirement System reported 0% of its portfolio in Navidea Biopharmaceuticals Inc (NYSEMKT:NAVB). Lynch Associate In holds 0% in Navidea Biopharmaceuticals Inc (NYSEMKT:NAVB) or 18,000 shares. Spark Invest Management Ltd Liability Company holds 0.02% of its portfolio in Navidea Biopharmaceuticals Inc (NYSEMKT:NAVB) for 420,000 shares. Manufacturers Life Insur Communications The holds 894 shares or 0% of its portfolio. Susquehanna Int Grp Inc Limited Liability Partnership invested in 0% or 26,101 shares. Blackrock Invest Lc invested in 27,075 shares or 0% of the stock. Commonwealth Equity owns 34,087 shares.

The stock of Navidea Biopharmaceuticals Incorporated (NYSEMKT:NAVB) registered a decrease of 1.04% in short interest. NAVB’s total short interest was 12.74M shares in July as published by FINRA. Its down 1.04% from 12.87M shares, reported previously. With 448,700 shares average volume, it will take short sellers 28 days to cover their NAVB’s short positions. The short interest to Navidea Biopharmaceuticals Incorporated’s float is 9.54%.

About 245,889 shares traded. Navidea Biopharmaceuticals Inc (NYSEMKT:NAVB) has declined 47.35% since July 17, 2016 and is downtrending. It has underperformed by 64.05% the S&P500.

Navidea Biopharmaceuticals, Inc. is a biopharmaceutical firm focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The company has market cap of $78.60 million. The Firm is developing multiple precision-targeted products based on the Manocept platform to help identify the sites and pathways of undetected disease. It currently has negative earnings. The Manocept platform is predicated on the ability to specifically target the CD206 mannose receptor expressed on activated macrophages.

More important recent Navidea Biopharmaceuticals Inc (NYSEMKT:NAVB) news were published by: Businesswire.com which released: “Navidea Biopharmaceuticals Reports First Quarter 2017 Financial Results” on May 09, 2017, also Marketwatch.com published article titled: “Navidea stock jumps 76% after company agrees to $80 million Cardinal Health deal”, Businesswire.com published: “Navidea Biopharmaceuticals to Hold Investor Update Call” on September 06, 2016. More interesting news about Navidea Biopharmaceuticals Inc (NYSEMKT:NAVB) was released by: Businesswire.com and their article: “Annual LD Micro Invitational Investor Conference” with publication date: June 01, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.